Mitigating Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): The Role of Bioactive Phytoconstituents in Indian Culinary Spices

Overview

Journal Curr Nutr Rep

Date 2025 Jan 22

PMID 39841356

Authors

Pervej Alom Barbhuiya

Ameena Ahmed

Partha Pratim Dutta

Saikat Sen

Manash Pratim Pathak

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: The term metabolic dysfunction-associated steatotic liver disease (MASLD) refers to a group of progressive steatotic liver conditions that include metabolic dysfunction-associated steatohepatitis (MASH), which has varying degrees of liver fibrosis and may advance to cirrhosis, and independent hepatic steatosis. MASLD has a complex underlying mechanism, with patients exhibiting diverse causes and phases of the disease. India has a pool prevalence of MASLD of 38.6% in adults. In 2023, the term NAFLD has been redefined and changed to MASLD. Currently, there are no drugs approved by the FDA for the treatment of MASLD. This study investigates the potential of bioactive phytoconstituents present in spices as a therapeutic approach for MASLD. Moreover, it offers comprehensive data on several pre-clinical studies of bioactive phytoconstituents derived from spices that primarily focus on treating obesity-associated MASLD.

Recent Findings: Spices include a high amount of bioactive chemicals and several research have indicated their diverse pharmacological activities. Bioactive phytoconstituents from common Indian spices like cinnamic acid, eugenol, curcumin, allicin, 6-gingerols, capsaicin, piperine, eucalyptol, trigonelline, and linalool have been reported to exhibit anti-MASLD effects both in-vivo and in-vitro. Bioactive phytoconstituents from different culinary species of India have shown promising potential against MASLD in pre-clinical status. Further clinical studies on a large scale would be beneficial for paving the path to the development of a new drug which is the need of time.

References

Clark J, Garvey W, Niswender K, Schmidt A, Ahima R, Aleman J . Obesity and Overweight: Probing Causes, Consequences, and Novel Therapeutic Approaches Through the American Heart Association's Strategically Focused Research Network. J Am Heart Assoc. 2023; 12(4):e027693. PMC: 10111504. DOI: 10.1161/JAHA.122.027693. View

Burelle C, Clapatiuc V, Deschenes S, Cuillerier A, De Loof M, Higgins M . A genetic mouse model of lean-NAFLD unveils sexual dimorphism in the liver-heart axis. Commun Biol. 2024; 7(1):356. PMC: 10959946. DOI: 10.1038/s42003-024-06035-6. View

Chan W, Chuah K, Rajaram R, Lim L, Ratnasingam J, Vethakkan S . Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review. J Obes Metab Syndr. 2023; 32(3):197-213. PMC: 10583766. DOI: 10.7570/jomes23052. View

Hagstrom H, Vessby J, Ekstedt M, Shang Y . 99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical. J Hepatol. 2023; 80(2):e76-e77. DOI: 10.1016/j.jhep.2023.08.026. View

Younossi Z, Paik J, Stepanova M, Ong J, Alqahtani S, Henry L . Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease. J Hepatol. 2024; 80(5):694-701. DOI: 10.1016/j.jhep.2024.01.014. View

Chen M, Zhu J, Mu W, Luo H, Li Y, Li S . Cdo1-Camkk2-AMPK axis confers the protective effects of exercise against NAFLD in mice. Nat Commun. 2023; 14(1):8391. PMC: 10728194. DOI: 10.1038/s41467-023-44242-7. View

Sun H, Kemper J . MicroRNA regulation of AMPK in nonalcoholic fatty liver disease. Exp Mol Med. 2023; 55(9):1974-1981. PMC: 10545736. DOI: 10.1038/s12276-023-01072-3. View

Metzger K, Crowley E, Kadlubowska D, Gooderham M . Uncommon Adverse Effects of Deoxycholic Acid Injection for Submental Fullness: Beyond the Clinical Trials. J Cutan Med Surg. 2020; 24(6):619-624. DOI: 10.1177/1203475420943270. View

Zhang C, Yang M . Current Options and Future Directions for NAFLD and NASH Treatment. Int J Mol Sci. 2021; 22(14). PMC: 8306701. DOI: 10.3390/ijms22147571. View

10.

Barbhuiya P, Laskar A, Mazumdar H, Dutta P, Pathak M, Dey B . Ethnomedicinal Practices and Traditional Medicinal Plants of Barak Valley, Assam: a systematic review. J Pharmacopuncture. 2022; 25(3):149-185. PMC: 9510141. DOI: 10.3831/KPI.2022.25.3.. View

11.

Khan S, Rai A, Singh A, Singh S, Dubey B, Lal R . Rapid metabolic fingerprinting with the aid of chemometric models to identify authenticity of natural medicines: Turmeric, , and study. J Pharm Anal. 2023; 13(9):1041-1057. PMC: 10568180. DOI: 10.1016/j.jpha.2023.04.018. View

12.

Chanu N, Gogoi P, Barbhuiya P, Dutta P, Pathak M, Sen S . Natural Flavonoids as Potential Therapeutics in the Management of Diabetic Wound: A Review. Curr Top Med Chem. 2023; 23(8):690-710. DOI: 10.2174/1568026623666230419102140. View

13.

Shi M, Gu J, Wu H, Rauf A, Emran T, Khan Z . Phytochemicals, Nutrition, Metabolism, Bioavailability, and Health Benefits in Lettuce-A Comprehensive Review. Antioxidants (Basel). 2022; 11(6). PMC: 9219965. DOI: 10.3390/antiox11061158. View

14.

Vasanthi H, Parameswari R . Indian spices for healthy heart - an overview. Curr Cardiol Rev. 2011; 6(4):274-9. PMC: 3083808. DOI: 10.2174/157340310793566172. View

15.

Al Dhaheri A, Alkhatib D, Jaleel A, Tariq M, Feehan J, Apostolopoulos V . Proximate composition and mineral content of spices increasingly employed in the Mediterranean diet. J Nutr Sci. 2023; 12:e79. PMC: 10388428. DOI: 10.1017/jns.2023.52. View

16.

Jiang T . Health Benefits of Culinary Herbs and Spices. J AOAC Int. 2019; 102(2):395-411. DOI: 10.5740/jaoacint.18-0418. View

17.

Fawzy M, Saeed N, El-Sherbiny D, El-Demerdash E . Eugenol modulates insulin sensitivity by upregulating insulin receptor substrate-2 in non-alcoholic fatty liver disease in rats. J Pharm Pharmacol. 2021; 73(6):846-854. DOI: 10.1093/jpp/rgab032. View

18.

Harb A, Bustanji Y, Almasri I, Abdalla S . Eugenol Reduces LDL Cholesterol and Hepatic Steatosis in Hypercholesterolemic Rats by Modulating TRPV1 Receptor. Sci Rep. 2019; 9(1):14003. PMC: 6768860. DOI: 10.1038/s41598-019-50352-4. View

19.

Fabbrini E, Sullivan S, Klein S . Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology. 2009; 51(2):679-89. PMC: 3575093. DOI: 10.1002/hep.23280. View

20.

Johnson A, Milner J, Makowski L . The inflammation highway: metabolism accelerates inflammatory traffic in obesity. Immunol Rev. 2012; 249(1):218-38. PMC: 3422768. DOI: 10.1111/j.1600-065X.2012.01151.x. View